ByTrending Posts
Dyno Therapeutics Reveals Roche’s Decision to Exercise Option…
January 13, 2025 Dyno Therapeutics has announced that Roche has exercised its option to license a novel AAV…
NVIDIA Joins Forces with Industry Leaders to Revolutionize…
J.P. Morgan Healthcare Conference — Jan 13, 2025 At the J.P. Morgan Healthcare Conference, NVIDIA unveiled transformative partnerships…
Insilico Medicine Identifies Novel Endometriosis Targets and Repurposes…
FLORENCE, Italy & CAMBRIDGE, Mass.— Jan 10, 2025AI-Driven Research Unveils New Therapeutic Approaches Researchers have leveraged artificial intelligence…
XtalPi and UCB Partner to Advance AI-Powered Biologic…
Cambridge, MA – Jan 10 2025 XtalPi Inc. (HKEX: 2228.HK), a leader in AI-powered pharmaceutical technology, announced a…
Can AI-Powered Drug Discovery Redefine Cardiometabolic Treatment? Novo…
Key Takeaways for Industry Leaders A Landmark Expansion: 20 Programs, $4.6 Billion, and a Bold Vision for AI…
Recursion Advances AI-Powered Oncology Pipeline with REC-3565 and…
Salt Lake City – January 7, 2025 Recursion, a clinical-stage TechBio company pioneering the integration of artificial intelligence…
Pfizer Expands Deal to $610M, AI Drug Discovery…
Boston – Jan 7, 2025 Strengthening AI-Driven Innovation in Small Molecules and ADCs Pfizer has expanded its partnership…
Terray’s AI-Driven Drug Discovery Platform Secures Collaboration with…
Boston – Dec 17, 2024 Strategic Expansion Following $120M Series B Terray Therapeutics is closing the year with…
Unlearn AI’s Breakthroughs in AI-Driven Clinical Development: 2024…
San Francisco – December 12, 2024 Unlearn AI has emerged as a leader in AI-powered clinical trial innovation,…
Trending Posts
Latest Stories
Did Immunology Approvals in 2025 Redefine Autoimmune Care—and Set the Stage for a New Growth Cycle in 2026?
Global – December 2025 — The immunology sector entered a decisive transformation in 2025, marked…
Did Oncology Approvals in 2025 Reshape the Competitive Landscape—and Set the Stage for a Breakthrough Cycle in 2026?
Global – December 2025 — The oncology sector reached a strategic inflection point in 2025,…
Can AI-Automated Hematology Redefine Laboratory Diagnostics? WORK Medical Secures Manufacturing Approval for Class II Blood Cell Analyzer
Hangzhou, China – December 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) today announced…
Phase 3 Clinical Trials of Setrusumab in Osteogenesis Imperfecta Fail to Meet Primary Endpoints
London & Novato, Calif. — December 2025 Mereo BioPharma Group plc (NASDAQ: MREO) and Ultragenyx…
Gallery
